{"id":"W2106185842","doi":"10.1212/wnl.0b013e3181e1cec2","title":"A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis","year":2010,"lang":"en","type":"article","venue":"Neurology","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":359,"is_retracted":false,"has_abstract":true,"ca_institutions":"Rockyview General Hospital; Hospital for Sick Children; McGill University; Etobicoke General Hospital; SickKids Foundation; University of Toronto; St. Michael's Hospital; Mount Sinai Hospital","funders":"Actelion Pharmaceuticals; National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Genentech; Multiple Sclerosis Society; National Institute of Diabetes and Digestive and Kidney Diseases; Multiple Sclerosis Society of Canada; EMD Serono; Elan; Immune Tolerance Network; Dairy Farmers of Canada; GlaxoSmithKline; Biogen; Sanofi; Teva Pharmaceutical Industries; Ono Pharmaceutical; Eli Lilly and Company","keywords":"Medicine; Tolerability; Vitamin D and neurology; Internal medicine; Expanded Disability Status Scale; Adverse effect; Clinical endpoint; Multiple sclerosis; Randomization; Vitamin; Clinical trial; Gastroenterology; Randomized controlled trial; vitamin D deficiency; Confounding; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002275747,0.002184115,0.002987262,0.000608681,0.0006646522,0.001041981,0.001125498,0.002110309,0.005939881],"category_scores_gemma":[0.001857738,0.0008460335,0.001264421,0.0004659869,0.001325148,0.000908926,0.0005356866,0.00387589,0.001016557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000755058,"about_ca_system_score_gemma":0.001220396,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007718101,"about_ca_topic_score_gemma":0.001353855,"domain_scores_codex":[0.9989594,0.0005707218,0.00005811893,0.000165353,0.00008332539,0.000163],"domain_scores_gemma":[0.9987423,0.0002753122,0.0002966626,0.0001587902,0.00008931891,0.0004376895],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9522053,0.02405501,0.0007926439,0.0002747703,0.0004717566,0.00004460534,0.00008350422,0.0003245002,0.007012361,0.00006245309,0.0007638905,0.0139092],"study_design_scores_gemma":[0.9267539,0.07116175,0.001092021,0.000009845076,0.00009191287,0.00002454068,0.000008537952,0.0001548419,0.0003868816,0.00004795383,0.0002616297,0.000006205559],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917786,0.001443052,0.0004523117,0.0006251207,0.000191584,0.003793927,0.0006752089,0.0001087853,0.0009313764],"genre_scores_gemma":[0.9820511,0.001406836,0.00242124,0.001530107,0.0004453527,0.007648293,0.001407738,0.00003276609,0.003056559],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005939881,"threshold_uncertainty_score":0.01987088,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07041064552524627,"score_gpt":0.3436837472503973,"score_spread":0.273273101725151,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}